Dominic Smethurst
Chief Tech/Sci/R&D Officer bij CORBUS PHARMACEUTICALS HOLDINGS, INC.
Vermogen: 3 M $ op 31-03-2024
Profiel
Dominic Smethurst is a Member at The Royal College of Physicians and a Member at the Faculty of Pharmaceutical Medicine.
He is also the Chief Medical Officer at Corbus Pharmaceuticals Holdings, Inc. since 2024.
Previously, he held positions such as Vice President-Oncology & Global Therapeutic Area at ICON plc, Chief Medical Officer at Bicycle Therapeutics Plc from 2020 to 2023, Chief Medical Officer at BerGenBio ASA, Chief Medical Officer at Nordic Nanovector ASA in 2020, and Chief Medical Officer at Tusk Therapeutics Ltd.
from 2016 to 2018.
Dr. Smethurst completed his undergraduate degree at the University of Cambridge and his graduate degree at Christ's College (United Kingdom).
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-02-2024 | 50 000 ( 0.48% ) | 2 M $ | 31-03-2024 | |
| 03-01-2023 | 23 574 ( 0.08% ) | 586 993 $ | 31-03-2024 |
Actieve functies van Dominic Smethurst
| Bedrijven | Functie | Begin |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 28-02-2024 |
| Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | - |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Eerdere bekende functies van Dominic Smethurst
| Bedrijven | Functie | Einde |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 31-03-2023 |
| THOR MEDICAL | Chief Tech/Sci/R&D Officer | 10-08-2020 |
Tusk Therapeutics Ltd.
 Tusk Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom. | Chief Tech/Sci/R&D Officer | 01-09-2018 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | - |
| ICON PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Opleiding van Dominic Smethurst
| University of Cambridge | Undergraduate Degree |
| Christ's College (United Kingdom) | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| ICON PUBLIC LIMITED COMPANY | Commercial Services |
| BICYCLE THERAPEUTICS PLC | Health Technology |
| BERGENBIO ASA | Health Technology |
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
| Faculty of Pharmaceutical Medicine | |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Tusk Therapeutics Ltd.
Tusk Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom. | Health Technology |
